A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

This study is testing a drug called GFH009 in people with peripheral T-cell lymphoma (PTCL), a type of aggressive blood cancer, that has returned or stopped responding to treatment. The study is looking at whether GFH009 is safe and effective for this group. **You may be eligible if...** - You are aged 18–75 - You have been confirmed to have relapsed or refractory peripheral T-cell lymphoma - You have received and failed at least 2 but no more than 5 prior treatments - You have at least one measurable tumor - You are in reasonable health (ECOG performance status 0–2) - Tumor tissue is available for testing - Your blood counts and organ function meet required levels - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have not previously received treatment for PTCL - You have had more than 5 prior lines of therapy - Your organ function does not meet study requirements - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.